GlassScriptPhysician profile
Collin Teguh
NPI 1639148828
$5,289.58
in general payments reported to CMS, 2019-2025
19 companies · $740 in 2025
The $740 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $405 · 2020: $906 · 2021: $705 · 2022: $1,003 · 2023: $873 · 2024: $658 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,270.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,403.89 | 2019-2025 | Descovy |
| Amgen INC. | $1,255.55 | 2019-2024 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $1,183.89 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $329.68 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $275.36 | 2019-2023 | Jardiance, Tradjenta |
| Viiv Healthcare Company | $188.63 | 2022-2025 | Apretude |
| Lilly USA, LLC | $171.76 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $88.75 | 2019-2022 | |
| Novo Nordisk INC | $71.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $50.79 | 2023-2025 | |
| Pfizer INC. | $50.16 | 2025 | |
| Abbvie INC. | $47.78 | 2022 | |
| Sunovion Pharmaceuticals INC. | $45.33 | 2020 | |
| Janssen Pharmaceuticals, INC | $40.70 | 2020 | |
| Boston Scientific Corporation | $23.38 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $20.68 | 2020 | |
| Abbott Laboratories | $15.99 | 2022 | |
| Dermira, INC. | $13.55 | 2020 | |
| Idorsia Pharmaceuticals US INC | $12.71 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Collin Teguh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.